Published on November 18, 2009 at 6:58 AM
Research and Markets (http://www.researchandmarkets.com/research/4e2e61/ophthalmic_pharmac) has announced the addition of the "Ophthalmic Pharmaceutical Drugs - A Global Market Perspective" report to their offering.
Prevention of blindness has emerged into a top health priority among aging citizens in the developed countries.
Increased healthcare spending in these countries is creating a strong demand for advanced ophthalmic therapeutic treatments.
This in turn is leading to the rise in investments in ophthalmic drug research, and a parallel spurt in the commercial availability of innovative and promising ocular drugs.
Ongoing research studies on developing pharmacologic IOP reducing drugs is expected to lead to the availability of powerful topical drugs with lesser side effects, and higher therapeutic efficacies, thereby overthrowing the present bottleneck of low patient compliance.
Pharmacodiversity and newer classes of potent drugs together, are expected to encourage patient compliance, and improve patient outcomes.
The market therefore is expected to get a much-awaited respite from the business, and economic repercussions of low patient compliance.
These and other market data and trends are presented in "Ophthalmic Pharmaceutical Drugs: A Global Market Perspective" by BizAcumen LLC.
Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
http://www.researchandmarkets.com/research/4e2e61/ophthalmic_pharmac